ANN ARBOR, Mich. and MUNICH, Germany, May 22, 2024 (GLOBE NEWSWIRE) -- Daiichi Sankyo Europe GmbH (hereafter, 'Daiichi Sankyo') and Esperion Therapeutics, Inc. jointly announced today that the European Commission (EC) has approved the label update of both NILEMDO® (bempedoic acid) and NUSTENDI® (bempedoic acid / ezetimibe fixed-dose combination (FDC)), as treatments for hypercholesterolemia (high levels of cholesterol) and to reduce the risk of adverse cardiovascular events. The EC's decisions to update the ...

ANN ARBOR, Mich., May 20, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) and Otsuka Pharmaceutical Co., Ltd (Otsuka) announced today that the primary endpoint was achieved in the Phase 3 trial in Japan for bempedoic acid as a potential treatment for patients with hypercholesterolemia. The trial demonstrated statistically significant outcomes on the primary endpoint for bempedoic acid and highlighted its potential future value to patients in Japan. INDICATION Bempedoic acid, created by Esperion Therapeutics ...

ANN ARBOR, Mich., May 20, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) and Otsuka Pharmaceutical Co., Ltd (Otsuka) announced today that the primary endpoint was achieved in the Phase 3 trial in Japan for bempedoic acid as a potential treatment for patients with hypercholesterolemia. The trial demonstrated statistically significant outcomes on the primary endpoint for bempedoic acid and highlighted its potential future value to patients in Japan. Bempedoic acid, created by Esperion Therapeutics, Inc. (Es ...

ANN ARBOR, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that on May 8, 2024, the Company granted 16 new employees 62,300 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such ind ...

Esperion Therapeutics, Inc. (ESPR) reported earnings of 34 cents per share in the first quarter of 2024, against the Zacks Consensus Estimate of a loss of 8 cents. The company incurred a loss of 79 cents per share in the year-ago quarter.Esperion generated revenues of $137.7 million, up nearly 467% year over year. The upside was driven by the receipt of a milestone payment and increased demand for the company’s drugs across all regions. Per management, this is the highest level of revenues generated by the ...

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Conference Call May 7, 2024 8:00 AM ET Company Participants Tiffany Aldrich - Associate Director, Corporate Communications Sheldon Koenig - President & Chief Executive Officer Ben Halladay - Chief Financial Officer Eric Warren - Chief Commercial Officer JoAnne Foody - Chief Medical Officer Conference Call Participants Dennis Ding - Jefferies Serge Belanger - Needham Tom Shrader - BTIG Jessica Fye - JPMorgan Joe Pantginis - H.C. Wainwright Jason Zema ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

ESPERION' REACHING GOALS Q1 2024 Earnings Presentation May 7, 2024 Forward-looking Statements & Disclosures This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, clinical development, including the timing, designs and plans for the CLEAR Outcomes study and its resu ...

Esperion Therapeutics (ESPR) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to loss of $0.79 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 525%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.53 per share when it actually produced a loss of $0.50, delivering a surprise of 5.66%.Over the last four ...

– Q1 Retail Prescription Equivalents Grew 43% Y/Y and 6% Q/Q, Increased Momentum from Label Expansions Expected Throughout 2024 – – Received U.S. FDA Approval of Broad New Label Expansions for NEXLETOL (bempedoic acid) Tablet and NEXLIZET (bempedoic acid and ezetimibe) Tablet, Becoming the First LDL-C Lowering Non- Statins to Prevent Heart Attacks and Reduce Cardiovascular Risk in Primary and Secondary Prevention Patients – ® ® Exhibit 99.1 Esperion Reports First Quarter 2024 Financial Results – Q1 Total Re ...